Eraquell 18.7 mg/g Oral Paste

Land: Storbritannien

Sprog: engelsk

Kilde: VMD (Veterinary Medicines Directorate)

Aktiv bestanddel:

Ivermectin

Tilgængelig fra:

Virbac

ATC-kode:

QP54AA01

INN (International Name):

Ivermectin

Lægemiddelform:

Oral paste

Recept type:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Terapeutisk gruppe:

Horses

Terapeutisk område:

Endectocide

Autorisation status:

Authorized

Autorisation dato:

2000-11-16

Produktets egenskaber

Revised: December 2015
AN: 01163/2015
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
ERAQUELL 18.7 mg/g Oral Paste
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Ivermectin
............................................................
18.7
mg/g.
EXCIPIENTS:
Titanium dioxide (E171) ......................................
0.02 g/g.
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Oral paste.
White and thick paste.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Roundworms in the stomach and intestines.
Large strongyles:
_Strongylus vulgaris: _adults and 4
th
larval (arterial) stages
_Strongylus edentatus: _adults and 4
th
larval (tissue) stages
_Strongylus equinus: _adults
Small strongyles, adults:
_Cyathostomum_ spp.
_Cylicocyclus_ spp.
_Cylicodontophorus_ spp.
_Cylicostephanus_ spp.
_Gyalocephalus _spp.
Hairworms:
_Trichostrongylus axei: _adults
Pinworms:
_Oxyuris equi: _adults and immatures
Ascarids:
_Parascaris equorum: _adults
Revised: December 2015
AN: 01163/2015
Page 2 of 6
Intestinal threadworms:
_Strongyloides westeri: _adults
Large-mouth stomach worms:
_Habronema muscae: _adults
Neck threadworms:
_Onchocerca_ spp. (microfilariae)
Lungworms:
_Dictyocaulus arnfieldi: _adult and immature
Stomach bots:
_Gasterophilus_ spp.: oral and gastric larval stages
4.3
CONTRA-INDICATIONS
Do not use in dogs or cats as severe adverse reactions may occur.
Do not use in cases of known hypersensitivity to the active substance.
See also section 4.11 “Withdrawal periods”.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Strategies that should be avoided because they might lead to an
increased risk of
development of resistance to anthelmintic drugs include:
•
Too frequent and repeated use of anthelmintics from the same class
over an
extended period of time.
•
Underdosing, which may be due to underestimation of body weight,
misadministration of the product, or lack of calibration of the dosi